Learn why these key experts can help optimize ANCA-associated vasculitis management.

Rituximab is linked to lower risks for renal complications than cyclophosphamide in adult patients with immunoglobulin A vasculitis.

Agency raised questions about avacopan's pivotal trial data and concerns of hepatotoxicity ...

This novel approach integrates diverse types of information by combining clinical parameters with imaging techniques like CT scans or laboratory data.

Read about reasons to feel hopeful about an ANCA-associated vasculitis diagnosis.

CHMP is reviewing avacopan, a drug authorized in the EU for treating adults with severe, active granulomatosis with polyangiitis or microscopic polyangiitis.

On Amgen's call, the company's head of R&D, Jay Bradner, said the FDA's request for a voluntary withdrawal on 16th January ...

ChemoCentryx, a part of Amgen, filed a patent infringement lawsuit against Zydus Pharmaceuticals on Jan. 16 in New Jersey District Court over Zydus's attempt to market a generic version of Tavneos, a ...

In this analysis of patients with myeloperoxidase-ANCA-positive AAV, all urinary complement C3 fragment levels were elevated significantly compared with healthy controls (P <.01 for all).

FDA requests Tavneos market withdrawal due to ADVOCATE trial assessment concerns; Amgen maintains the drug's benefit-risk profile remains positive.

The uptick in Leqembi (lecanemab) sales comes a few months after the FDA approved a once-weekly subcutaneous injection ...

Amgen declines FDA request to withdraw Tavneos, citing strong clinical data and real-world evidence supporting its safety and effectiveness.